The trial used an "all-comers" design and excluded patients with previous interventions or acute myocardial infarction without consulting local doctors. Patients assigned to one treatment but receiving another or neither were analyzed based on their assigned treatment. The study also included registries of patients not eligible for randomization due to clinical characteristics, including those not suitable for CABG due to comorbidities or no graft material or for PCI due to complex anatomy or untreated chronic total occlusions. The primary endpoint was a composite of death, stroke, heart attack, or revascularization over 12 months as adjudicated by an independent committee.